Zevra Therapeutics, Inc.ZVRA

Zevra Therapeutics reported $37.9 million in net income for the quarter ended 31 March 2026, according to its latest 10-Q, while its cash and equivalents stood at $95.6 million-numbers that would make even a seasoned biotech CFO pause to admire the balance sheet like a freshly polished lab bench. Operating income clocked in at $52.1 million for the same period, and shareholders’ equity reached $205.8 million, all of which suggests a company that is either genuinely efficient or simply very good at keeping its spending in check while the website does the talking. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1434647/000143464724000045/zvra-20260630x10q.htm)

What Zevra actually does, according to its own copy, is advance promising medicines through complex clinical and regulatory terrain, balancing science with patient need. The website highlights a Phase 3 trial of Celiprolol in Vascular Ehlers-Danlos Syndrome and a Phase 2 programme for KP1077 in Idiopathic Hypersomnia, backed by a DiSCOVER trial designed to evaluate efficacy and safety. These are real programmes, but they are also pre-commercial, meaning the company’s revenue story remains a work in progress. The product pages and clinical trial links are polished, but they do not yet translate into filed sales data or named commercial partners with disclosed contracts. (source: Zevra Therapeutics, Clinical Trials, https://zevra.com/clinical-trials)

The filings tell a different story. The 10-Q for the quarter ending March 2026 lists operating income of $52.1 million, net income attributable to parent of $37.9 million, and diluted EPS of $0.60 on 60.2 million weighted average shares. Cash provided by operating activities was $6.1 million, while capital expenditure was a mere $35,000-so modest it barely registers on a biotech’s typical burnometer. Inventory stood at $2.3 million, up $185,000 from the prior period, which is either a sign of supply chain prudence or the quiet hum of a company preparing for something larger. Liabilities totalled $72.8 million against $278.6 million in assets, leaving shareholders with $205.8 million in equity, a figure that looks impressive until you notice the absence of revenue lines. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1434647/000143464724000045/zvra-20260630x10q.htm)

For a closer look at Zevra’s market footprint, follow the SEC filings index or the company’s submissions JSON feed, both of which catalogue the filing trail but not the product. The SEC’s Company Facts JSON aggregates structured data points like net income and EPS, yet it stops short of disclosing customer names, contract values, or even the existence of a single commercial launch. The gap between disclosure and hype is the real clinical trial here: the company’s narrative is locked in a Phase 3 of its own making. (source: SEC EDGAR, Company Facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001434647.json)

What changed this week is less a market catalyst and more a filing cadence. Zevra filed a Form 144 on 8 July 2026 and multiple Form 4s on 18 and 23 June 2026, all of which document insider activity but do not yet link to revenue milestones or product approvals. The company’s website remains the primary conduit for its public story, but the site’s elegant language lacks the granularity of the SEC’s dry numbers. Until the filings include revenue, contract details, or customer names, the market will continue to trade the narrative while the balance sheet quietly ticks over. (source: SEC EDGAR, Filing index, https://www.sec.gov/edgar/browse/?CIK=1434647)

What remains unproven is whether Zevra’s pipeline will yield commercial products, whether its partnered revenue streams are material, and whether the board’s enthusiasm for per diem-style executive incentives will survive the next audit. The clinical programmes are real, the cash is real, and the hype is real-but the revenue, so far, is not. Until the company files evidence of sales or binding contracts, the balance sheet will remain the only thing breaking even. (source: Zevra Therapeutics, Our Products, https://zevra.com/our-products/)